Berlin

• Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Ended recruitment
  2023-504359-29-01 5 2024-12-11 Multiple sclerosis
• Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 W … Ended recruitment
  2023-505110-14-00 4 2024-12-02 Colorectal Cancer
• A study looking at how effective and safe AZD7798 is in people with Crohn's disease Ended recruitment
  2023-510487-12-00 4 2024-11-29 Crohn's Disease
• Safety and efficacy of the FTP-002 / FTP-501 combination in the treatment of glabellar lines. Ended recruitment
  2023-507249-27-00 7 2024-11-26 glabellar lines.
• A multi-center, open-label extension study of subcutaneous secukinumab to evaluate the long-term safety and tolerability in polymyalgia rheu … Ended recruitment
  2023-508077-85-00 5 2024-11-19 Polymyalgia Rheumatica
• Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Ended recruitment
  2024-514343-29-00 5 2024-11-19 multiple sclerosis
• A randomized, controlled study to evaluate LNP023 (iptacopan) in patients with active ANCA-associated vasculitis. Ended recruitment
  2023-510525-15-00 4 2024-11-18 active antineutrophilic cytoplasmic antibody (ANCA) associated vasculi
• RCT of Medical Cannabis Aerosol for DPNP Treatment Ended recruitment
  2023-508932-68-00 4 2024-11-14 Diabetic Peripheral Neuropathic Pain
• Transmural Healing and Disease Modifying Effect of Guselkumab in Crohn’s Disease Patients Ended recruitment
  2023-504040-34-01 5 2024-11-12 Crohn’s Disease
• GenePHIT: A study to learn more about how well a new gene therapy (AB-1002) works and its safety in participants with congestive heart failu … Ended recruitment
  2024-510581-17-00 4 2024-11-05 Adult subjects with New York Heart Association (NYHA) Class III conges
• Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-4 Study) Ended recruitment
  2023-509301-80-00 5 2024-11-04 Severe hypertriglyceridemia (SHTG)
• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis Ended recruitment
  2024-510753-10-00 5 2024-11-01 Prurigo Nodularis
• Tuvusertib Combined with Niraparib or Lartesertib in Participants with Epithelial Ovarian Cancer (DDRiver EOC 302) Ended recruitment
  2024-511202-23-00 4 2024-10-31 Epithelial ovarian cancer that progressed on prior PARP inhibitor ther
• Phase III Clinical Trial for CPX-351 in Myeloid Leukemia in Children with Down Syndrome 2018 Ended recruitment
  2022-501457-37-00 5 2024-10-28 Myeloid Leukemia in Children with Down Syndrome
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended recruitment
  2023-508636-61-00 5 2024-10-24 Crohn’s Disease
• A Phase 3 study to evaluate the Efficacy and Safety of Efgartigimod IV in Patients with Acetylcholine Receptor Binding Antibody Seronegative … Ended recruitment
  2024-511796-15-00 5 2024-10-16 Acetylcholine Receptor Binding Antibody Seronegative Generalized Myast
• A Phase 2a/b study of the efficacy and safety of subcutaneous amlitelimab in adults with non-responsive celiac disease Ended recruitment
  2024-511213-38-00 4 2024-10-15 Coeliac disease
• Efficacy and safety of oral minoxidil in women with hormone-imbalanced hair loss Ended recruitment
  2023-503383-17-01 5 2024-10-10 Female androgenetic alopecia
• A phase 1/2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic Gastrointestinal cancers exploring treatment … Ended recruitment
  2024-515936-62-00 9 2024-10-10 Patients with advanced or metastatic gastrointestinal (GI) tumors.
• A phase Ib, open-label, ascending dose study with step-up doses to assess safety, tolerability, and pharmacokinetics of PIT565 in participan … Ended recruitment
  2023-510025-14-00 3 2024-10-08 Systemic Lupus Erythematosus
• Frontline Asciminib combination in chronic phase CML Ended recruitment
  2024-516212-24-00 4 2024-10-08 Chronic Myeloid Leukemia
• An Open-label, Phase I/II Multicenter Clinical Trial of NECVAX-NEO1 in Addition to Anti-PD-1 or Anti-PD-L1 Monoclonal Antibody Therapy in Pa … Ended recruitment
  2024-511212-24-00 9 2024-10-07 Advanced solid tumors
• A study to learn how bimekizumab works in people with moderate to severe plaque psoriasis. Ended recruitment
  2023-506333-29-00 11 2024-10-01 Moderate to Severe Plaque Psoriasis
• Long-term Follow-up Study of Male Adults with Hemophilia B Previously Treated with Etranacogene Dezaparvovec (CSL222) Ended recruitment
  2023-503765-37-00 10 2024-09-30 Hemophilia B

Showing 937–960 of 1,776 trials